In September 2025, the Russian personalized mRNA vaccine will be used in an experimental mode. The Ministry of Health’s permission is expected in August, but the plan is still awaiting approval.
Clinical trials of the new drug will start with patients suffering from melanoma and small cell lung cancer. At the same time, the therapy will be available, including to those who have already undergone certain stages of treatment.
This drug is the product of a collaborative effort among experts from the Gamaleya Center, the Herzen Moscow Oncology Research Institute, and the Blokhin National Medical Research Center of Oncology. The technology is based on an mRNA platform that provides a high concentration of the target antigen in cells.
The development is protected by Russian patents and is an independent technological solution. The state will incur a cost of approximately 300,000 rubles for each individual cancer vaccine, yet patients will receive this life-saving treatment at no charge.
